Cannabis Extract in Refractory Epilepsy Study

Status Terminated

Clinical Trial Summary

The purpose of this study is to examine whether a low dose of CBD+THC will decrease the frequency of convulsive seizures in adults with drug-resistant epilepsy, when used in addition to standard anti-epileptic drugs (AEDs). This study will also study the genes associated with epilepsy and whether different epileptic syndromes respond to treatment with CBD+THC.

Clinical Trial Description

Background: Cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) are the two major compounds found in the cannabis plant. Reports from patients, families, and the scientific community suggest that CBD (when used as an add-on therapy) decreases the number of convulsive seizures in children and adults with Dravet syndrome, Lennox-Gastaut syndrome, and Tuberous sclerosis complex.

Trial design: Phase III, double-blind, randomized, placebo-controlled, parallel-group trial, followed by an open phase where treatment allocation will be revealed and all participants will either continue or begin receiving the active study drug.

Participants: Adults (18 years of age and older) with drug-resistant epilepsy, including patients with Dravet and Lennox Gastaut syndromes, and patients with frequent convulsive seizures (e.g., tonic, tonic-clonic, atonic, drop attacks, and focal motor seizures).

Interventions: Capsules containing a ratio of 16 CBD: 1 THC oil at a maximum total daily dose of approximately 300 mg of CBD per day, divided into equal doses in the morning and evening.

Comparator: Placebo capsules containing high-oleic sunflower oil and no active or medicinal ingredients.

Outcomes: Frequency of seizures; side effects; blood levels of AEDs, CBD, THC, and liver enzymes; impact on cognition and quality of life; genetics.

Sample size: A total of 80 participants (40 assigned to treatment and 40 to control group) recruited from Toronto Western Hospital in Toronto, and University Hospital in London, Ontario.

Time: Each participant will be enrolled for approximately 16 to 18 weeks, while the clinical trial is expected to take place over a period of two years. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03808935
Study type	Interventional
Source	The Epilepsy Research Program of the Ontario Brain Institute
Contact
Status	Terminated
Phase	Phase 3
Start date	January 10, 2019
Completion date	March 15, 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04378075` - A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy	Phase 2/Phase 3
Recruiting	`NCT05928598` - Goals for Epilepsy Clinic Visits Trial	N/A
Recruiting	`NCT05539287` - Clinical Study Evaluating the Safety of Lactobacillus Probiotic in Children With Drug Resistant Epilepsy	Phase 2
Not yet recruiting	`NCT04601974` - Lentiviral Gene Therapy for Epilepsy	Phase 1/Phase 2
Completed	`NCT02982824` - Effect of Magnesium Supplementation for Children With Drug Resistant Idiopathic Epilepsy	N/A
Recruiting	`NCT05485558` - the Safety and Efficacy of N-acetyl Cysteine in Children With Drug-Resistant Epilepsy	Phase 2
Not yet recruiting	`NCT04553354` - Cortical Resections in Drug Resistant Epilepsy
Recruiting	`NCT04999046` - NaviFUS™ System Neuromodulating Treatment for Patients With Drug Resistant Epilepsy	N/A
Recruiting	`NCT04714996` - Efficacy, Safety and Pharmacokinetics of ES-481 in Adult Patients With Drug Resistant Epilepsy	Phase 2
Recruiting	`NCT04839601` - RNS System RESPONSE Study	N/A
Recruiting	`NCT06059157` - Epileptogenic Network Visualisation With Advanced MRI	N/A
Recruiting	`NCT05947656` - Evaluation of the NaviFUS System in Drug Resistant Epilepsy	N/A
Recruiting	`NCT05393518` - Electroclinical Correlation of Anxiety	N/A
Not yet recruiting	`NCT05555537` - MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy
Completed	`NCT03419000` - Circulating microRNAs as Biomarkers of RESPIratory Dysfunction in Patients With Refractory epilePSY	N/A
Enrolling by invitation	`NCT06341075` - Real-World Study of Magnetic Resonance-guided Laser Interstitial Thermal Therapy for Drug-resistant Epilepsy	N/A
Not yet recruiting	`NCT05527093` - Cartography of Social Cognition Network and Their Alterations in Patients With Epilepsy	N/A
Recruiting	`NCT05697614` - The Benefit and Safety of Older Generation Anti-Epileptic Drugs (AEDs) in Drug-Resistant Epilepsy Children	Phase 4
Recruiting	`NCT06309251` - Effectiveness and Impact on the Quality of Life of Ketogenic Diet in Pediatric Patients
Recruiting	`NCT06432907` - StereoEEG Motor Neuronal Potentials Decoding	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Cannabis Extract in Refractory Epilepsy Study — CERES

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms